Core Insights - EirGenix Inc. has entered into a second global exclusive licensing agreement with Sandoz AG for the commercialization of its breast cancer biosimilar EG1206A, covering all territories except specific Asian markets [1][2] - The agreement includes up to USD 152 million in upfront and milestone payments, along with profit sharing and sales incentives post-launch [1][2] - EG1206A has received positive feedback from the U.S. FDA and EMA, allowing for an abbreviated development pathway without Phase III trials [2] Company Developments - EirGenix has successfully developed multiple biosimilar products using reverse engineering technologies, enhancing its global competitiveness [5] - The company is accelerating the development of four HER2-targeted antibody programs and expanding its product pipeline and CDMO services [5] - EirGenix's production capacity and facilities have attracted attention from international pharmaceutical companies, indicating strong growth potential [5] Market Context - There are approximately 2.3 million breast cancer patients globally, with 20% diagnosed with HER2-positive disease, indicating a significant market for EG1206A [3] - The combination therapy of Trastuzumab and Pertuzumab is the current standard of care, with potential market expansion for EG1206A as new treatment options emerge [3] - Roche's Perjeta® generated global sales of approximately USD 4 billion in 2024, highlighting the lucrative market for HER2-targeted therapies [3][4] Strategic Partnership - The partnership with Sandoz strengthens the existing collaboration, following a previous agreement for EG12014, which is already approved in Europe and under review in the U.S. [2] - Sandoz is a leader in affordable medicines, with a portfolio of around 1,300 products and net sales of USD 10.4 billion in 2024 [4]